Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
Ciclopirox doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2000–2026 with a typical study size of 460 participants.
Based on 21 studies · 3 meta-analyses · 6 RCTs · 13,919 total participants
Study base
21 studies indexed
By outcome
Every outcome below: Too few graded studies.
Hair & nails12 studies
12 studies
Safety profile3 studies
3 studies
Glucose & metabolic1 study
1 study
Skin health1 study
1 study
Oral & dental health1 study
1 study
Active research area
13 studies in the last 5 years · Latest meta-analysis: 2025
200020132026
1Meta-AnalysisCited 42×n=12,501 · very large study2020
In plain English: Compared with vehicle, ciclopirox 8% lacquer may be more effective in achieving complete cure (risk ratio 9.29, 95% CI 1.72 to 50.14; low-quality evidence) and is probably more effective in achieving mycological cure (RR 3.15, 95% CI 1.93 to 5.12; moderate-quality evidence).
Foley K, et al. · Cochrane Database Syst Rev (2020)
56 studies, 12,501 participants. Only three were rated low risk of bias across all domains; the commonest high-risk domain was performance bias.
The headline complete-cure risk ratio of 9.29 carries a confidence interval from 1.72 to 50.14 and is rated low quality. A relative effect that large on a small absolute base is not a precise estimate.
Mycological cure is the firmer finding: RR 3.15 (95% CI 1.93 to 5.12), moderate quality, from two studies and 460 participants.
In plain English: No statistically significant differences were observed between patient groups in the proportion of subjects achieving a complete cure.
Sánchez-Regaña M, et al. · Mycoses (2023)
Phase III, multicentre, randomised, double-blind, 381 patients, 48 weeks of treatment with follow-up to week 52.
The primary complete-cure endpoint was null across the new hydrolacquer, its vehicle and the active comparator.
On mycological cure it was NOT null: the hydrolacquer alone was significantly superior to vehicle for negativising dermatophyte culture (p = .039), at 32.0% against 23.2% vehicle and 27% reference.
In plain English: Fluconazole, efinaconazole, ciclopirox, terbinafine nail solution, and amorolfine treatments were significantly superior to only placebo.
Gupta AK, et al. · J Am Podiatr Med Assoc (2015)
Network meta-analysis, needed because onychomycosis treatments are seldom compared head to head.
12-week continuous oral terbinafine 250 mg was superior to all treatments except itraconazole 400 mg pulse therapy.
Ciclopirox beat placebo and nothing else. The abstract describes the topical therapies as equivalent to one another.
4ReviewCited 68×2000
In plain English: The combined results show a 34% mycologic cure rate, as compared with 10% for the placebo.
Gupta AK, et al. · J Am Podiatr Med Assoc (2000)
Reports the two pivotal US double-blind vehicle-controlled trials behind the FDA approval, alongside ten studies conducted worldwide.
Combined US mycological cure 34% against 10% on vehicle.
The worldwide meta-analytic mean of 52.6% ± 4.2% is a separate figure from the 34% US result and should not be read as the same quantity.
5ReviewCited 164×n=460 · medium study2000
In plain English: At the end of the 48-week treatment period, the mycologic cure rate in study I was 29% vs 11% in the ciclopirox and vehicle groups, respectively. Similarly, the mycologic cure rate for study II was 36% vs 9%.
Gupta AK, Joseph WS · J Am Acad Dermatol (2000)
Reviews two identically designed double-blind vehicle-controlled multicentre US trials, 223 and 237 patients randomised, alongside studies run outside the US.
Entry required clinical features plus positive microscopy AND positive dermatophyte culture, with 20% to 65% of the target nail involved.
Daily application for 48 weeks to all toenails and affected fingernails.
6Meta-Analysis2025
In plain English: Additional clinical trials are needed on photodynamic therapy, topical plant products, and topical antimicrobials.
Xin YH, Ying TJ, Syeed MS, Veettil SK, Menon RK. · The Journal of prosthetic dentistry (2025)
Topical antifungals ranked highest in the SUCRA ranking for clinical improvement, whereas microwave disinfection concurrently administered with topical antifungal agents ranked highest for mycological resolution.
None of the agents demonstrated significant side effects except for topical antimicrobial agents which demonstrated altered taste and staining of oral structures.
Conclusions Available evidence suggests that topical antifungals, microwave, and systemic antifungals are effective in the treatment of DS, but confidence in these findings is low because of the limited number of studies and a high risk of bias.
In plain English: The superiority of P-3051 vs. reference was nearly significant at week 48 (confirmed at week 52), and it was significant at week 60 (cure rate for P-3051 is 119% higher than reference; P < 0.05).
Baran R, et al. · J Eur Acad Dermatol Venereol (2009)
Multicentre randomised three-arm placebo-controlled evaluator-blinded trial, 467 patients, 48 weeks of treatment plus 12 weeks of follow-up.
P-3051 met its objective: superior to placebo and non-inferior to the marketed 8% lacquer on complete cure at week 48.
The superiority claim rests on week 60, twelve weeks after treatment stopped, having been only 'nearly significant' at the week-48 endpoint.
8RCT2025
In plain English: Treatment of onychomycosis using diode laser and photodynamic therapy results in higher clinical cure rates and shorter healing times compared to the reference treatment with 8% ciclopirox HPCH.
Objective To evaluate the clinical efficacy of combining diode laser therapy with photodynamic therapy and ciclopirox 8% hydroxypropyl chitosan (HPCH) nail lacquer in treating onychomycosis.
Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with ciclopirox 8% HPCH.
Results The clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to 53.3% in the group treated with ciclopirox 8% HPCH (p = 0.008).
In plain English: Topical therapy can be considered a treatment option for mild to moderate onychomycosis, even though effective delivery of the drug is restricted by the nail's barrier properties.
Verma S, Kumar N, Sharma A, Agarwal S. · Recent advances in drug delivery and formulation (2026)
Efinaconazole solution (10%), tavaborole solution (5%), and ciclopirox nail lacquer (8%) for topical use are accepted by the Food and Drug Administration (FDA) for the management of onychomycosis.
Laser treatment is approved in the United States for the short-term improvement of clear nails in fungal infections, but the clinical outcomes have not yet reached optimal levels.
Conclusion Topical therapy can be considered a treatment option for mild to moderate onychomycosis, even though effective delivery of the drug is restricted by the nail's barrier properties.
In plain English: Together, these advances position formulation science as a key driver of innovation in next generation of antifungal therapy.
Dc R et al. · International journal of nanomedicine (2026)
Particular emphasis is placed on nanotechnology-based drug delivery systems, biofilm-targeting strategies, stimuli-responsive platforms, and combination therapies.
The review further highlights the emerging role of artificial intelligence (AI)-driven formulation design, predictive modeling, and precision therapeutics in advancing antifungal treatment.
The integration of nanotechnology, AI-driven computational modeling, and precision therapeutics offers new opportunities to improve efficacy, reduce toxicity, and enable more personalized antifungal treatment.
In plain English: This review provides an in-depth overview of the epidemiology, diagnosis, and management of onychomycosis in special populations, underscoring the importance of individualized care to improve outcomes and reduce recurrence.
Gupta AK, Liddy A, Wang T, Cooper EA. · Future microbiology (2025)
Treatment must be tailored to individual risk profiles, with careful consideration of drug efficacy, safety, and potential interactions with comorbidities and polypharmacy.
While systemic antifungals remain the standard for moderate-to-severe disease, their use may be limited by comorbidities, such as renal and hepatic impairment, and drug interactions.
Topical antifungals such as efinaconazole, tavaborole, and ciclopirox can be considered for mild to moderate onychomycosis.
In plain English: While many superficial Candida infections can be managed with hygiene practices and topical antifungal treatments, invasive candidiasis necessitates close collaboration between microbiology, pharmacology, and infectious disease specialists to ensure optimal patient care.
Müller VL, Kreuter A, Uhrlaß S, Nenoff P. · Dermatologie (Heidelberg, Germany) (2025)
Given the rising rates of resistance and the associated therapeutic challenges, accurate species identification and resistance profiling prior to antifungal treatment are critical.
Preventive measures, especially for high-risk populations, are crucial to reduce the incidence of Candida infections.
While many superficial Candida infections can be managed with hygiene practices and topical antifungal treatments, invasive candidiasis necessitates close collaboration between microbiology, pharmacology, and infectious disease specialists to ensure optimal patient care.
In plain English: Topical ciclopirox, efinaconazole and tavaborole, delivered either alone or in combination with oral antifungals, have demonstrated efficacy in vitro against susceptible and/or resistant isolates of Trichophyton species, with low potential for development of antifungal resistance.
Gupta AK, Elewski B, Joseph WS, Lipner SR, Daniel CR, Tosti A, Guenin E, Ghannoum M. · Mycoses (2024)
Antifungal stewardship efforts aim to ensure proper antifungal use to limit antifungal resistance and improve clinical outcomes.
In the treatment of onychomycosis, critical aspects of antifungal stewardship include proper identification of the fungal infection prior to initiation of treatment and improvements in physician and patient education.
Topical ciclopirox, efinaconazole and tavaborole, delivered either alone or in combination with oral antifungals, have demonstrated efficacy in vitro against susceptible and/or resistant isolates of Trichophyton species, with low potential for development of antifungal resistance.
In plain English: These innovative approaches offer new perspectives for the treatment of nail diseases, facilitating the development of more effective formulations.
de Monte Vidal V, Otero XG, Tomé VD, Viaño IS, Rodríguez SC, Igea SA, Lajarin-Reinares M, Herrero M, Camprodo XJ, Otero Espinar FJ. · International journal of pharmaceutics (2026)
This review includes a description of the microstructural alterations caused by diseases such as onychomycosis and psoriasis, which can change nail permeability affecting the efficacy of topical treatments.
It also reviews strategies to improve drug penetration, highlighting the use of hydromiscible vehicles based on cyclodextrin polypseudorataxanes or hydroxypropyl chitosan, and the use of chemical promoters such as sodium lauryl sulfate.
Finally, advances in nail lacquer formulations are discussed, including those based on hydroxypropyl chitosan and cyclodextrin pseudopolyrotaxanes, which have been shown to improve the absorption and efficacy of topical antifungal treatments and therapies for nail disorders.
In plain English: Antifungal stewardship, including avoiding the use of combination antifungal-corticosteroids, should be emphasized to optimize outcomes and help prevent resistance.
Caplan AS, Gold JAW, Smith DJ, Ely JW. · American family physician (2025)
Oral terbinafine is considered first-line therapy for tinea capitis and onychomycosis because it is well tolerated, effective, and inexpensive.
Emerging tinea infections may be more severe than classic tinea infections and generally do not improve with first-line topical or oral antifungals.
These infections may require prolonged oral antifungal therapy and specialized diagnostic testing.
17Review2025
In plain English: A shared decision-making framework can help improve treatment compliance and patient satisfaction.
Gupta AK, Taylor D, Dennis D, Wang T, Cooper EA. · Journal of fungi (Basel, Switzerland) (2025)
Novel topical antifungals, such as efinaconazole 10% approved for use in North America and Japan, offer a safe treatment option for many of these patients, though real-world use requires special considerations.
In children and adolescents (≥6 years), efinaconazole 10% has shown higher efficacy rates than in adults, possibly attributed to less nail trauma, thinner nail plates, and faster nail growth.
Efinaconazole 10% showed similar efficacy in this population, regardless of glycemic control.
In plain English: By integrating current clinical data, this review aims to provide clinicians with a more comprehensive and effective approach to treatment, with the goal of improving the clinical outcomes and quality of life for patients with diabetic onychomycosis.
Li Y, Qiu J, Shen Y, Tan W, Zhang J. · Clinical, cosmetic and investigational dermatology (2026)
This review systematically examines the therapeutic options specifically for diabetic onychomycosis.
We will review traditional treatment methods, including oral and topical antifungal drugs, with a particular focus on their safety and drug-drug interactions.
Besides, we also explored emerging new therapeutic strategies, such as laser therapy, photodynamic therapy (PDT), and surgical approaches.
In plain English: Mycologic cure was 70% in the treated group and 20% in the vehicle arm (p = 0.03) at week 12. At end of the study (week 32), 77% of treated patients achieved mycologic cure and 71% effective treatment, compared with 22% of the control.
Friedlander SF, et al. · Pediatr Dermatol (2013)
Prospective randomised double-blind vehicle-controlled trial in 40 children aged 2 to 16 with non-matrix onychomycosis, randomised 1:3.
Mycological cure 70% against 20% at week 12 (p = 0.03), and 77% against 22% at week 32.
The protocol included weekly lacquer removal and mechanical trimming, which is more than most people do at home.
20RCTCited 16×n=70 · small study2005
In plain English: Using an intent to treat analysis, there was no significant difference in proportion of persons ulcerating in the AFL versus the NAFL groups (5.9% versus 5.6% P = 0.9).
Armstrong DG, et al. · Int Wound J (2005)
70 people at high risk of diabetic foot ulceration, randomised to daily self-inspection with or without ciclopirox 8%, followed for 12 months or until ulceration.
No reduction in ulceration. This is included because the hypothesis is attractive and the answer was negative.
Significantly fewer patients had clinically diagnosed hyperkeratosis or tinea pedis at study end, 52.9% against 77.8% (P = 0.03).